Chemical proteomics and its application to drug discovery.

The completion of the human genome sequencing project has provided a flood of new information that is likely to change the way scientists approach the study of complex biological systems. A major challenge lies in translating this information into new and better ways to treat human disease. The multidisciplinary science of chemical proteomics can be used to distill this flood of new information. This approach makes use of synthetic small molecules that can be used to covalently modify a set of related enzymes and subsequently allow their purification and/or identification as valid drug targets. Furthermore, such methods enable rapid biochemical analysis and small-molecule screening of targets thereby accelerating the often difficult process of target validation and drug discovery.

[1]  J. V. Moran,et al.  Initial sequencing and analysis of the human genome. , 2001, Nature.

[2]  N. Dracopoli,et al.  Applied genomics: integration of the technology within pharmaceutical research and development. , 2000, Current opinion in biotechnology.

[3]  S. Withers,et al.  Suicide inactivation of human prostatic acid phosphatase and a phosphotyrosine phosphatase. , 1994, Biochemical and biophysical research communications.

[4]  M. Zvelebil,et al.  Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction , 1996, Molecular and cellular biology.

[5]  S Toba,et al.  Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. , 2000, Chemistry & biology.

[6]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[7]  A. Goldberg,et al.  Covalent modification of the active site threonine of proteasomal beta subunits and the Escherichia coli homolog HslV by a new class of inhibitors. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Benjamin F. Cravatt,et al.  Chemical strategies for the global analysis of protein function. , 2000 .

[9]  P. A. Nielsen,et al.  Defining a Link between Gap Junction Communication, Proteolysis, and Cataract Formation* , 2001, The Journal of Biological Chemistry.

[10]  J. Dixon,et al.  Protein tyrosine phosphatases: mechanisms of catalysis and regulation. , 1998, Current opinion in chemical biology.

[11]  Nasreen S Jessani,et al.  Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Burlingame,et al.  Chemical Approaches for Functionally Probing the Proteome* , 2002, Molecular & Cellular Proteomics.

[13]  P. Traxler,et al.  ATP site‐directed competitive and irreversible inhibitors of protein kinases , 2000, Medicinal research reviews.

[14]  R. Lerner,et al.  Chemical Selection for Catalysis in Combinatorial Antibody Libraries , 1997, Science.

[15]  A. Burlingame,et al.  Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. , 2000, Chemistry & biology.

[16]  P. Griffin,et al.  Inactivation of interleukin-1 beta converting enzyme by peptide (acyloxy)methyl ketones. , 1994, Biochemistry.

[17]  B. Cravatt,et al.  Profiling serine hydrolase activities in complex proteomes. , 2001, Biochemistry.

[18]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[19]  Richard D. Smith,et al.  Stable isotope-coded proteomic mass spectrometry. , 2003, Current opinion in biotechnology.

[20]  J. Burbaum,et al.  Direct visualization of serine hydrolase activities in complex proteomes using fluorescent active site‐directed probes , 2001, Proteomics.

[21]  R. Levesque,et al.  Molecular basis of antibiotic resistance and beta-lactamase inhibition by mechanism-based inactivators: perspectives and future directions. , 2000, FEMS microbiology reviews.

[22]  C. Walsh.  Suicide substrates, mechanism-based enzyme inactivators: recent developments. , 1984, Annual Review of Biochemistry.

[23]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[24]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[25]  B. Cravatt,et al.  Proteomic profiling of mechanistically distinct enzyme classes using a common chemotype , 2002, Nature Biotechnology.

[26]  M. Mann,et al.  What does it mean to identify a protein in proteomics? , 2002, Trends in biochemical sciences.

[27]  A. Alonso,et al.  Protein tyrosine phosphatases. , 2002, Frontiers in bioscience : a journal and virtual library.

[28]  Timothy B. Stockwell,et al.  The Sequence of the Human Genome , 2001, Science.

[29]  Scott Myers,et al.  Drug discovery—an operating model for a new era , 2001, Nature Biotechnology.

[30]  H. Ploegh,et al.  A novel active site‐directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14 , 2001, The EMBO journal.

[31]  R. Colman.  Affinity labeling of purine nucleotide sites in proteins. , 1983, Annual review of biochemistry.

[32]  M. Wilchek,et al.  Introduction to avidin-biotin technology. , 1990, Methods in enzymology.

[33]  H. Ploegh,et al.  Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. , 2002, Chemistry & biology.

[34]  J. Betley,et al.  Direct Screening for Phosphatase Activity by Turnover-Based Capture of Protein Catalysts This work was supported by BBSRC studentships (to J.B. and H.D.), by an EPSRC studentship (to J.H.R.), and by an EC TMR studentship (to S.C.-T.). , 2002 .

[35]  Ruedi Aebersold,et al.  Quantitative proteome analysis by solid-phase isotope tagging and mass spectrometry , 2002, Nature Biotechnology.

[36]  T. Reiss.  Drug discovery of the future: the implications of the human genome project. , 2001, Trends in biotechnology.

[37]  M. Mann,et al.  Proteomics to study genes and genomes , 2000, Nature.

[38]  S. Taylor,et al.  Affinity labeling of cAMP-dependent protein kinase with p-fluorosulfonylbenzoyl adenosine. Covalent modification of lysine 71. , 1981, The Journal of biological chemistry.

[39]  R. Colman.  Chemical arrows for enzymatic targets , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  D. Pei,et al.  α-Haloacetophenone Derivatives As Photoreversible Covalent Inhibitors of Protein Tyrosine Phosphatases , 1999 .

[41]  Martin Norin,et al.  Structural proteomics: developments in structure-to-function predictions. , 2002, Trends in biotechnology.

[42]  J. Betley,et al.  Direct screening for phosphatase activity by turnover-based capture of protein catalysts. , 2002, Angewandte Chemie.

[43]  A. McCluskey,et al.  Serine-threonine protein phosphatase inhibitors: development of potential therapeutic strategies. , 2002, Journal of medicinal chemistry.

[44]  M. Hohenegger,et al.  Covalent modification of G-proteins by affinity labeling. , 2004, Methods in molecular biology.

[45]  B. Cravatt,et al.  Activity-based protein profiling: the serine hydrolases. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Yuri Lazebnik,et al.  Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells , 1997, The EMBO journal.

[47]  S. Gygi,et al.  Mass spectrometry and proteomics. , 2000, Current opinion in chemical biology.